Sanofi commits ‘at least $20bn' to US manufacturing through 2030
Sanofi has become the latest big pharma company to boost manufacturing in the US with a hefty investment as the biopharma industry safeguards itself against the continued threat of pharma tariffs from President Donald Trump.
The French drugmaker said it would commit at least $20bn in the US through 2030, with the aim to increase R&D and manufacturing capabilities.
Sanofi's current sites in the US stand to benefit from direct investments as the company looks to enhance the robustness of its medicine supply chain amid an uncertain trade landscape.
There are 83,000 people employed by Sanofi worldwide – 13,000 of whom are based in the US. While the vaccine maker has not publicly disclosed the exact size of its US manufacturing and R&D footprint, its website lists six major locations across three states.
Sanofi's innovation hub, which employs 2,500 people, is based in Cambridge, Massachusetts. Swiftwater, Pennsylvania contains the company's vaccine production sites, whilst Framingham, Massachusetts houses a biologics factory. Also in Massachusetts is Sanofi's Waltham facility, responsible for developing mRNA technology. Sanofi's US headquarters is in Bridgewater, New Jersey.
Alongside levelling up existing sites, Sanofi stated it would expand its US presence via partnerships with other domestic manufacturers.
Sanofi's CEO Paul Hudson said: 'Our expected investments in the US will be substantial and will help ensure the production of key medicines in the US."
Companies are moving quickly to shore up US manufacturing capabilities amid tariffs implemented by Trump that have made importing certain products into the country less attractive. The biopharma industry is also bracing itself for pharmaceutical-specific tariffs, a levy continually threatened by Trump. The President signed an executive order last week that will see foreign drug manufacturing plants receive the same level of scrutiny and surprise inspections as US-based facilities, a bid to boost domestic manufacturing.
Sanofi stated that its investment decisions 'will be adjusted as the external environment continues to evolve'. In 2024, $21.6bn of its $45.2bn global sales came from the US market.
Sanofi joins a long list of pharma and life science companies redirecting resources to the US in an effort to make supply chains more robust. In April, Roche unveiled a $50bn investment strategy to upgrade three R&D sites in the US. Thermo Fisher has outlaid $2bn to bolster US manufacturing, whilst Novartis, Johnson & Johnson and Eli Lilly have also made respective investment announcements in 2025. The medtech industry is also following in the same vein – Siemens Healthineers said yesterday (14 May) it would relocate manufacturing from Mexico to the US for one of its subsidiaries.
Navigate the shifting tariff landscape with real-time data and market-leading analysis.
Request a free demo for GlobalData's Strategic Intelligence here.
"Sanofi commits 'at least $20bn' to US manufacturing through 2030" was originally created and published by Pharmaceutical Technology, a GlobalData owned brand.
The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Miami Herald
29 minutes ago
- Miami Herald
Trump order seeks to boost U.S. drone industry
June 7 (UPI) -- President Donald Trump is taking aim at drone technology from two directions -- boost the U.S. industry and crack down on malicious activity. Trump on Friday signed executive orders on efforts to spur U.S. production relevant to drone technology, increase U.S. drone security and regulation efforts, and an unleated one to promote design and eventual use of commercial supersonic aircraft. "Unmanned aircraft systems, otherwise known as drones, offer the potential to enhance public safety as well as cement America's leadership in global innovation," an executive order titled Restoring American Airspace Sovereignty read. "But criminals, terrorists, and hostile foreign actors have intensified their weaponization of these technologies, creating new and serious threats to our homeland. Another order, titled Unleashing American Drone Dominance, declares that "building a strong and secure domestic drone sector is vital to reducing reliance on foreign sources, strengthening critical supply chains and ensuring that the benefits of this technology are delivered to the American people." There are more than a million registered drones in the United States, according to the FAA with more than 400,000 commercial drones and more than 350,000 for recreational use. In a press release, the Commercial Drone Alliance said it has "believed that innovation and security are two sides of the same coin. Outdated regulations have long impeded technological innovation and hindered transparency in our airspace." Lisa Ellman, chief executive of the Commercial Drone Alliance, also lauded the executive orders for aiming at both innovation and security simultaneously. "We fully support the long-overdue steps taken by the Trump administration in these Executive Orders -- establishing a framework to scale safe and secure drone operations while enhancing drone security and airspace transparency -- to modernize our domestic drone policy and assure American aviation leadership into the next century of flight," she said in the release. Drone dangers Trump has warned that drones have been used to smuggle drugs across borders, and could threaten large public gatherings, such as the 2026 World Cup and the 2028 Summer Olympics, both in the United States. "It is the policy of the United States to ensure control over our national airspace and to protect the public, critical infrastructure, mass gathering events, and military and sensitive government installations and operations from threats posed by the careless or unlawful use of UAS," the security related order reads. Chinese-made drones from companies like DJI or Autel are not outright banned, but the Federal Acquisition Security Council has been called on to "publish a Covered Foreign Entity List ... identifying companies that pose supply chain risks." In 2022, the U.S. Treasury added DJI and seven other companies to its Chinese Military-Industrial Complex list, which indicates some level of national security concern. The includes a ban on U.S.-based companies exporting technology to them. The majority of drones are estimated to be built in China, The New York Times reported. The Justice Department and FAA were told to enforce civil and criminal penalties for drone operators who violate laws or airspace restrictions. There will be grants for state and local law enforcement to access drone-detection and tracking equipment. The Federal Aviation Administration requires all drones weighing more than 0.55 of a pound to be registered, in addition to restricting how high they can be flown without authorization. The Justice Department and FAA were told to more robustly enforce civil and criminal penalties for drone operators who violate laws or airspace restrictions. Grant programs are planned for state and local law enforcement to access drone-detection and tracking equipment., the order also indicates Drone industry growth In his first term, Trump sought to increase the use of drones and Commerce Secretary Howard Lutnick has been directed to promote exports of U.S.-made drones, in addition to federal agencies being ordered to prioritize purchases of them. "The United States must accelerate the safe commercialization of drone technologies and fully integrate UAS into the National Airspace System," the order reads. "The time has come to accelerate testing and to enable routine drone operations, scale up domestic production, and expand the export of trusted, American-manufactured drone technologies to global markets." The order directs the FAA to allow commercial users and public safety officials not to fly drones beyond their range of sight, meaning that a user must be able to see the drone they are operating. "Building a strong and secure domestic drone sector is vital to reducing reliance on foreign sources, strengthening critical supply chains, and ensuring that the benefits of this technology are delivered to the American people," the order says. Secretary of Transportation Sean Duffy was directed to initiate artificial intelligence tools to assist in and expedite the review of a UAS waiver application, and the Transportation Department was told to develop an Electric Vertical Takeoff and Landing Pilot Program to accelerate the deployment of safe and lawful eVTOL operations in the United States. Supersonic flight An additional executive order titled "Leading the World in Supersonic Flight" seeks to promise planes that travel at supersonic speeds, which are greater than the speed of sound at approximately 768 mph at sea level, or Mach 1. "The United States stands at the threshold of a bold new chapter in aerospace innovation," the order reads. "For more than 50 years, outdated and overly restrictive regulations have grounded the promise of supersonic flight over land, stifling American ingenuity, weakening our global competitiveness, and ceding leadership to foreign adversaries." The order noted that "advances in aerospace engineering, materials science, and noise reduction now make supersonic flight not just possible, but safe, sustainable, and commercially viable." The order repeals regulations prohibiting cross-country supersonic flights, which for decades have precluded nonmilitary air travel over land at faster-than-sound speeds. The Concorde was manufactured from 1965 to 1979, but are no longer flown by airlines, however, Boom Supersonic and NASA are currently developing new supersonic passenger jets. Copyright 2025 UPI News Corporation. All Rights Reserved.
Yahoo
30 minutes ago
- Yahoo
Newsmax Stock Is Set to Join the U.S. Small-Cap Russell 2000 Index in Less Than a Month. Time to Buy?
Newsmax stock has steadily declined since a brief surge after its IPO. The stock trades at a premium valuation. It's delivering solid growth, but traditional media has been a challenging industry for investors. 10 stocks we like better than Newsmax › Newsmax (NYSE: NMAX) has only been a publicly traded company for a couple of months, but it's stuffed a lot of excitement into a short period of time. After pricing its shares at $10 on March 31, the stock skyrocketed to $233 over a two-day trading frenzy before plunging back down to earth. A limited float, high demand, interest in a conservative media brand, and the meme stock effect all combined to send the stock briefly soaring. Since then, Newsmax has gradually declined, closing at $18.09 a share on June 4, though that's still up more than 80% from its IPO price. However, Newsmax shareholders did get some good news recently. The stock is set to join the small-cap Russell 2000 index at the end of the month, meaning that exchange-traded funds (ETFs) that track the index will have to buy shares of Newsmax, which should help boost the stock price. With Newsmax getting some recognition from the best-known small-cap index, it's a good time to ask if the stock is worth buying. Here's what you need to know about Newsmax. IPOs for traditional media companies aren't particularly common in the current era, but Newsmax seemed to see an opportunity to capitalize on interest in conservative media brands in the wake of President Donald Trump's election, and it has so far paid off. In addition to the core broadcasting business, which includes two linear cable channels and a streaming channel, Newsmax also has a digital business, Humanix Publishing, that includes a print and e-book publishing house; Medix Health, which sells 22 nutraceutical products aimed at Newsmax's demographic; an advertising and media strategy business; and an insurance agency, Crown Atlantic Insurance, that primarily sells life insurance and retirement solutions like annuities. As a business, Newsmax's growth has been surprisingly strong; total revenue rose 26% last year to $171 million. Advertising revenue, which makes up the majority of its revenue, was essentially flat, but revenue from affiliate fees surged due to new contractual relationships that began in late 2023. On an adjusted earnings before interest, taxes, depreciation, and amortization (EBITDA) basis, it flipped a $10.4 million loss in 2023 to a $10.3 million profit in 2024, due to strong performance in the broadcasting division. Newsmax is now the fourth-highest-rated cable news channel in the U.S., and had 33.6 million viewers in the first quarter. Revenue rose 12% in the first quarter to $45.3 million. Newsmax aims to grow in a number of ways, including expanding the Newsmax audience, growing its premium content to build its subscription business, and expanding its television and digital offerings. Even with some impressive audience growth numbers, including a 50% jump in viewers in the first quarter, traditional television media is a tough sell in this day and age, and Newsmax seems destined to fight an uphill battle even if the political climate remains favorable. For example, viewership could have jumped in the first quarter due to the inauguration or interest in Trump. Investors shouldn't assume that that growth rate is sustainable over the long term. The company's lack of a generally accepted accounting principles (GAAP) profit is also concerning; it lost $72.2 million last year, though that was due in part to a one-time net costs increase of $53 million related to legal fees for the settlement of the Smartmatic lawsuit. In the first quarter, it lost $17.2 million. Additionally, the timing of the IPO, when there was considerable interest in Trump and related businesses, won't help the business over the long term. Overall, Newsmax could be successful despite the larger media industry headwinds, but the stock isn't even an attractive value right now, trading at a price-to-sales ratio of 14. At a better valuation and with a GAAP profit, Newsmax might be worth taking a small position in. While gaining admission into the Russell 2000 is a step in the right direction, it's not enough to make the stock a buy. Before you buy stock in Newsmax, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Newsmax wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $669,517!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $868,615!* Now, it's worth noting Stock Advisor's total average return is 792% — a market-crushing outperformance compared to 171% for the S&P 500. Don't miss out on the latest top 10 list, available when you join . See the 10 stocks » *Stock Advisor returns as of June 2, 2025 Jeremy Bowman has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. Newsmax Stock Is Set to Join the U.S. Small-Cap Russell 2000 Index in Less Than a Month. Time to Buy? was originally published by The Motley Fool
Yahoo
40 minutes ago
- Yahoo
Dupixent® (dupilumab) Data at Revolutionizing Atopic Dermatitis (RAD) Conference Reinforce Use in Atopic Dermatitis Patients with Skin of Color
Atopic dermatitis is a chronic disease that disproportionately impacts communities of color Dupixent achieved 75% or greater improvement in overall disease severity, the primary endpoint, in more than three-quarters of treated patients Patients experienced substantial reductions in hyperpigmentation, dry skin and itch from baseline Results support commitment to enhance clinical understanding of chronic diseases in communities of color TARRYTOWN, N.Y. and PARIS, June 07, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today presented results from the DISCOVER Phase 4, single-arm, open-label trial assessing Dupixent® (dupilumab) in adults and adolescents with moderate-to-severe atopic dermatitis with skin of color. These are the first clinical trial results for Dupixent in a large population of patients with darker skin tones. The results, along with the Dupixent Phase 3 trials, demonstrated patients taking Dupixent experienced improvements in signs and symptoms of atopic dermatitis from baseline across many skin tones. The data were shared in an oral presentation at the 2025 Revolutionizing Atopic Dermatitis (RAD) Conference. 'Atopic dermatitis, a chronic disease with underlying type 2 inflammation, has a high prevalence and quality of life impact on patients with skin of color. Unique clinical features like darker patches of hyperpigmentation versus redness typically seen on lighter skin may lead to less accurate diagnoses and underestimation of disease severity,' said Andrew Alexis, M.D., M.P.H., Professor of Clinical Dermatology at Weill Cornell Medicine. 'The results from the DISCOVER trial showed that Dupixent patients with atopic dermatitis and darker skin not only experienced reduced disease severity and itch but also saw improvements in areas of particular concern including dyspigmentation and dry skin. These data deepen the clinical understanding of atopic dermatitis within this underserved population, including use of newly validated scales.' In the trial, 120 patients with atopic dermatitis and skin of color (82% Black, 11% Asian, 2% American Indian/Alaska Native, 5% Arab, Central American or other) were treated with Dupixent every two weeks using a weight-based dosing regimen. At 24 weeks: 76% achieved a ≥75% improvement in overall disease severity (EASI-75), the primary endpoint. Improvements were seen by some patients as early as two weeks. 53% achieved clinically meaningful improvement in itch (≥4-point reduction on the peak-pruritus numerical rating scale [PP-NRS]). Improvements were seen by some patients as early as two weeks. Patients experienced a 53% reduction from baseline in post-inflammatory hyperpigmentation, dropping from 5.1 points (moderate/marked) to 2.4 points (mild). 18% were very or extremely bothered by dry skin vs. 78% at baseline, based on patient reporting. The safety results in the DISCOVER trial were generally consistent with the known safety profile of Dupixent in its approved dermatological indications. The overall rate of adverse events (AEs; n=124) in the DISCOVER trial was 42%, with the most common (≥2%) AEs being headache (3%), upper respiratory tract infection (2%), eczema (2%), conjunctivitis (3%) and allergic conjunctivitis (2%). About Atopic Dermatitis in Skin of ColorAtopic dermatitis is a chronic skin disease with underlying type 2 inflammation that causes intense, persistent itch and skin lesions that cover much of the body, resulting in skin dryness, cracking, pain, crusting and oozing. In patients with skin of color, the type and location of the lesions can vary, and they are more likely to have hardened skin lesions and severe skin dryness, itch, dyspigmentation and greater disease severity than those with lighter skin. Additionally, redness that is observed on lighter skin typically appears as darkened, grey or violet on darker skin tones. Because the disease presents differently in people with skin of color, it can be misdiagnosed or the severity underestimated, which can contribute to higher levels of healthcare resource utilization. About the DISCOVER Clinical TrialThe DISCOVER Phase 4 open-label, single-arm trial evaluated the efficacy and safety of Dupixent in adults and adolescents aged 12 years and older with moderate-to-severe atopic dermatitis and skin of color, as defined by Fitzpatrick skin types IV-VI (those with high melanin; light brown to black). During the 24-week treatment period, all patients in the trial received Dupixent monotherapy every two weeks based on weight after a loading dose: patients weighing ≥30 to <60 kg received 200 mg and patients weighing ≥60 kg received 300 mg. The primary endpoint assessed the proportion of patients who achieved at least 75% improvement on the Eczema Area and Severity Index (EASI-75) at 24 weeks. Secondary endpoints included the proportion of patients who achieved ≥4-point improvement on the Peak-Pruritus Numerical Rating Scale (PP-NRS) at 24 weeks. Additional endpoints included pigmentary changes on the clinician-reported Post-Inflammatory Hyperpigmentation Severity Scale (PHSS; scale: 0-8) and skin dryness on the newly developed patient-reported Xerosis NRS (X-AD; scale: 0-10) at 24 weeks. About DupixentDupixent, which was invented using Regeneron's proprietary VelocImmune® technology, is a fully human monoclonal antibody that inhibits the signaling of the interleukin-4 (IL-4) and interleukin-13 (IL-13) pathways and is not an immunosuppressant. The Dupixent development program has shown significant clinical benefit and a decrease in type 2 inflammation in Phase 3 trials, establishing that IL-4 and IL-13 are two of the key and central drivers of the type 2 inflammation that plays a major role in multiple related and often co-morbid diseases. Dupixent has received regulatory approvals in more than 60 countries in one or more indications including certain patients with atopic dermatitis, asthma, chronic rhinosinusitis with nasal polyps (CRSwNP), eosinophilic esophagitis (EoE), prurigo nodularis, chronic spontaneous urticaria (CSU) and chronic obstructive pulmonary disease (COPD) in different age populations. More than 1,000,000 patients are being treated with Dupixent globally.1 About Regeneron's Technology Regeneron's VelocImmune technology utilizes a proprietary genetically engineered mouse platform endowed with a genetically humanized immune system to produce optimized fully human antibodies. When Regeneron's co-Founder, President and Chief Scientific Officer George D. Yancopoulos was a graduate student with his mentor Frederick W. Alt in 1985, they were the first to envision making such a genetically humanized mouse, and Regeneron has spent decades inventing and developing VelocImmune and related VelociSuite® technologies. Dr. Yancopoulos and his team have used VelocImmune technology to create a substantial proportion of all original, FDA-approved fully human monoclonal antibodies. This includes Dupixent® (dupilumab), Libtayo® (cemiplimab-rwlc), Praluent® (alirocumab), Kevzara® (sarilumab), Evkeeza® (evinacumab-dgnb), Inmazeb® (atoltivimab, maftivimab and odesivimab-ebgn) and Veopoz® (pozelimab-bbfg). In addition, REGEN-COV® (casirivimab and imdevimab) had been authorized by the FDA during the COVID-19 pandemic until 2024. Dupilumab Development Program Dupilumab is being jointly developed by Regeneron and Sanofi under a global collaboration agreement. To date, dupilumab has been studied across more than 60 clinical trials involving more than 10,000 patients with various chronic diseases driven in part by type 2 inflammation. In addition to the currently approved indications, Regeneron and Sanofi are studying dupilumab in a broad range of diseases driven by type 2 inflammation or other allergic processes in Phase 3 trials, including chronic pruritus of unknown origin, bullous pemphigoid, and lichen simplex chronicus. These potential uses of dupilumab are currently under clinical investigation, and the safety and efficacy in these conditions have not been fully evaluated by any regulatory authority. U.S. INDICATIONS DUPIXENT is a prescription medicine used: to treat adults and children 6 months of age and older with moderate-to-severe eczema (atopic dermatitis or AD) that is not well controlled with prescription therapies used on the skin (topical), or who cannot use topical therapies. DUPIXENT can be used with or without topical corticosteroids. It is not known if DUPIXENT is safe and effective in children with atopic dermatitis under 6 months of age. with other asthma medicines for the maintenance treatment of moderate-to-severe eosinophilic or oral steroid dependent asthma in adults and children 6 years of age and older whose asthma is not controlled with their current asthma medicines. DUPIXENT helps prevent severe asthma attacks (exacerbations) and can improve your breathing. DUPIXENT may also help reduce the amount of oral corticosteroids you need while preventing severe asthma attacks and improving your breathing. It is not known if DUPIXENT is safe and effective in children with asthma under 6 years of age. with other medicines for the maintenance treatment of chronic rhinosinusitis with nasal polyps (CRSwNP) in adults and children 12 years of age and older whose disease is not controlled. It is not known if DUPIXENT is safe and effective in children with chronic rhinosinusitis with nasal polyps under 12 years of age. to treat adults and children 1 year of age and older with eosinophilic esophagitis (EoE), who weigh at least 33 pounds (15 kg). It is not known if DUPIXENT is safe and effective in children with eosinophilic esophagitis under 1 year of age, or who weigh less than 33 pounds (15 kg). to treat adults with prurigo nodularis (PN). It is not known if DUPIXENT is safe and effective in children with prurigo nodularis under 18 years of age. with other medicines for the maintenance treatment of adults with inadequately controlled chronic obstructive pulmonary disease (COPD) and a high number of blood eosinophils (a type of white blood cell that may contribute to your COPD). DUPIXENT is used to reduce the number of flare-ups (the worsening of your COPD symptoms for several days) and can improve your breathing. It is not known if DUPIXENT is safe and effective in children with chronic obstructive pulmonary disease under 18 years of age. to treat adults and children 12 years of age and older with chronic spontaneous urticaria (CSU) who continue to have hives that are not controlled with H1 antihistamine treatment. It is not known if DUPIXENT is safe and effective in children with chronic spontaneous urticaria under 12 years of age, or who weigh less than 66 pounds (30 kg). DUPIXENT is not used to relieve sudden breathing problems and will not replace an inhaled rescue medicine. DUPIXENT is not used to treat any other forms of hives (urticaria). IMPORTANT SAFETY INFORMATION Do not use if you are allergic to dupilumab or to any of the ingredients in DUPIXENT®. Before using DUPIXENT, tell your healthcare provider about all your medical conditions, including if you: have eye problems. have a parasitic (helminth) infection. are scheduled to receive any vaccinations. You should not receive a 'live vaccine' right before and during treatment with DUPIXENT. are pregnant or plan to become pregnant. It is not known whether DUPIXENT will harm your unborn baby. A pregnancy registry for women who take DUPIXENT during pregnancy collects information about the health of you and your baby. To enroll or get more information call 1-877-311-8972 or go to are breastfeeding or plan to breastfeed. It is not known whether DUPIXENT passes into your breast milk. Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. Especially tell your healthcare provider if you are taking oral, topical, or inhaled corticosteroid medicines; have asthma and use an asthma medicine; or have atopic dermatitis, chronic rhinosinusitis with nasal polyps, eosinophilic esophagitis, prurigo nodularis, chronic obstructive pulmonary disease, or chronic spontaneous urticaria, and also have asthma. Do not change or stop your other medicines, including corticosteroid medicine or other asthma medicine, without talking to your healthcare provider. This may cause other symptoms that were controlled by those medicines to come back. DUPIXENT can cause serious side effects, including: Allergic reactions. DUPIXENT can cause allergic reactions that can sometimes be severe. Stop using DUPIXENT and tell your healthcare provider or get emergency help right away if you get any of the following signs or symptoms: breathing problems or wheezing, swelling of the face, lips, mouth, tongue or throat, fainting, dizziness, feeling lightheaded, fast pulse, fever, hives, joint pain, general ill feeling, itching, skin rash, swollen lymph nodes, nausea or vomiting, or cramps in your stomach-area. Eye problems. Tell your healthcare provider if you have any new or worsening eye problems, including eye pain or changes in vision, such as blurred vision. Your healthcare provider may send you to an ophthalmologist for an exam if needed Inflammation of your blood vessels. Rarely, this can happen in people with asthma who receive DUPIXENT. This may happen in people who also take a steroid medicine by mouth that is being stopped or the dose is being lowered. Tell your healthcare provider right away if you have: rash, chest pain, worsening shortness of breath, brown or dark colored urine, persistent fever, or a feeling of pins and needles or numbness of your arms or legs. Psoriasis. This can happen in people with atopic dermatitis and asthma who receive DUPIXENT. Tell your healthcare provider about any new skin symptoms. Your healthcare provider may send you to a dermatologist for an examination if needed. Joint aches and pain. Some people who use DUPIXENT have had trouble walking or moving due to their joint symptoms, and in some cases needed to be hospitalized. Tell your healthcare provider about any new or worsening joint symptoms. Your healthcare provider may stop DUPIXENT if you develop joint symptoms. The most common side effects include: Eczema: injection site reactions, eye and eyelid inflammation, including redness, swelling, and itching, sometimes with blurred vision, dry eye, cold sores in your mouth or on your lips, and high count of a certain white blood cell (eosinophilia). Asthma: injection site reactions, high count of a certain white blood cell (eosinophilia), pain in the throat (oropharyngeal pain), and parasitic (helminth) infections. Chronic Rhinosinusitis with Nasal Polyps: injection site reactions, eye and eyelid inflammation, including redness, swelling, and itching, sometimes with blurred vision, high count of a certain white blood cell (eosinophilia), gastritis, joint pain (arthralgia), trouble sleeping (insomnia), and toothache. Eosinophilic Esophagitis: injection site reactions, upper respiratory tract infections, cold sores in your mouth or on your lips, and joint pain (arthralgia). Prurigo Nodularis: eye and eyelid inflammation, including redness, swelling, and itching, sometimes with blurred vision, herpes virus infections, common cold symptoms (nasopharyngitis), dizziness, muscle pain, and diarrhea. Chronic Obstructive Pulmonary Disease: injection site reactions, common cold symptoms (nasopharyngitis), high count of a certain white blood cell (eosinophilia), viral infection, back pain, inflammation inside the nose (rhinitis), diarrhea, gastritis, joint pain (arthralgia), toothache, headache, and urinary tract infection. Chronic Spontaneous Urticaria: injection site reactions. Tell your healthcare provider if you have any side effect that bothers you or that does not go away. These are not all the possible side effects of DUPIXENT. Call your doctor for medical advice about side effects. You are encouraged to report negative side effects of prescription drugs to the FDA. Visit or call 1-800-FDA-1088. Use DUPIXENT exactly as prescribed by your healthcare provider. It's an injection given under the skin (subcutaneous injection). Your healthcare provider will decide if you or your caregiver can inject DUPIXENT. Do not try to prepare and inject DUPIXENT until you or your caregiver have been trained by your healthcare provider. In children 12 years of age and older, it's recommended DUPIXENT be administered by or under supervision of an adult. In children 6 months to less than 12 years of age, DUPIXENT should be given by a caregiver. Please see accompanying full Prescribing Information including Patient Information. About RegeneronRegeneron (NASDAQ: REGN) is a leading biotechnology company that invents, develops and commercializes life-transforming medicines for people with serious diseases. Founded and led by physician-scientists, our unique ability to repeatedly and consistently translate science into medicine has led to numerous approved treatments and product candidates in development, most of which were homegrown in our laboratories. Our medicines and pipeline are designed to help patients with eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, neurological diseases, hematologic conditions, infectious diseases, and rare diseases. Regeneron pushes the boundaries of scientific discovery and accelerates drug development using our proprietary technologies, such as VelociSuite, which produces optimized fully human antibodies and new classes of bispecific antibodies. We are shaping the next frontier of medicine with data-powered insights from the Regeneron Genetics Center® and pioneering genetic medicine platforms, enabling us to identify innovative targets and complementary approaches to potentially treat or cure diseases. For more information, please visit or follow Regeneron on LinkedIn, Instagram, Facebook or X. About Sanofi Sanofi is an R&D driven, AI-powered biopharma company committed to improving people's lives and delivering compelling growth. We apply our deep understanding of the immune system to invent medicines and vaccines that treat and protect millions of people around the world, with an innovative pipeline that could benefit millions more. Our team is guided by one purpose: we chase the miracles of science to improve people's lives; this inspires us to drive progress and deliver positive impact for our people and the communities we serve, by addressing the most urgent healthcare, environmental, and societal challenges of our time. Sanofi is listed on EURONEXT: SAN and NASDAQ: SNY. Regeneron Forward-Looking Statements and Use of Digital Media This press release includes forward-looking statements that involve risks and uncertainties relating to future events and the future performance of Regeneron Pharmaceuticals, Inc. ('Regeneron' or the 'Company'), and actual events or results may differ materially from these forward-looking statements. Words such as 'anticipate,' 'expect,' 'intend,' 'plan,' 'believe,' 'seek,' 'estimate,' variations of such words, and similar expressions are intended to identify such forward-looking statements, although not all forward-looking statements contain these identifying words. These statements concern, and these risks and uncertainties include, among others, the nature, timing, and possible success and therapeutic applications of products marketed or otherwise commercialized by Regeneron and/or its collaborators or licensees (collectively, 'Regeneron's Products') and product candidates being developed by Regeneron and/or its collaborators or licensees (collectively, 'Regeneron's Product Candidates') and research and clinical programs now underway or planned, including without limitation Dupixent® (dupilumab); uncertainty of the utilization, market acceptance, and commercial success of Regeneron's Products and Regeneron's Product Candidates and the impact of studies (whether conducted by Regeneron or others and whether mandated or voluntary), including the studies discussed or referenced in this press release, on any of the foregoing; the likelihood, timing, and scope of possible regulatory approval and commercial launch of Regeneron's Product Candidates and new indications for Regeneron's Products, such as Dupixent for the treatment of chronic pruritus of unknown origin, bullous pemphigoid, lichen simplex chronicus, and other potential indications; the ability of Regeneron's collaborators, licensees, suppliers, or other third parties (as applicable) to perform manufacturing, filling, finishing, packaging, labeling, distribution, and other steps related to Regeneron's Products and Regeneron's Product Candidates; the ability of Regeneron to manage supply chains for multiple products and product candidates and risks associated with tariffs and other trade restrictions; safety issues resulting from the administration of Regeneron's Products (such as Dupixent) and Regeneron's Product Candidates in patients, including serious complications or side effects in connection with the use of Regeneron's Products and Regeneron's Product Candidates in clinical trials; determinations by regulatory and administrative governmental authorities which may delay or restrict Regeneron's ability to continue to develop or commercialize Regeneron's Products and Regeneron's Product Candidates; ongoing regulatory obligations and oversight impacting Regeneron's Products, research and clinical programs, and business, including those relating to patient privacy; the availability and extent of reimbursement or copay assistance for Regeneron's Products from third-party payors and other third parties, including private payor healthcare and insurance programs, health maintenance organizations, pharmacy benefit management companies, and government programs such as Medicare and Medicaid; coverage and reimbursement determinations by such payors and other third parties and new policies and procedures adopted by such payors and other third parties; changes in laws, regulations, and policies affecting the healthcare industry; competing drugs and product candidates that may be superior to, or more cost effective than, Regeneron's Products and Regeneron's Product Candidates (including biosimilar versions of Regeneron's Products); the extent to which the results from the research and development programs conducted by Regeneron and/or its collaborators or licensees may be replicated in other studies and/or lead to advancement of product candidates to clinical trials, therapeutic applications, or regulatory approval; unanticipated expenses; the costs of developing, producing, and selling products; the ability of Regeneron to meet any of its financial projections or guidance and changes to the assumptions underlying those projections or guidance; the potential for any license, collaboration, or supply agreement, including Regeneron's agreements with Sanofi and Bayer (or their respective affiliated companies, as applicable), to be cancelled or terminated; the impact of public health outbreaks, epidemics, or pandemics on Regeneron's business; and risks associated with litigation and other proceedings and government investigations relating to the Company and/or its operations (including the pending civil proceedings initiated or joined by the U.S. Department of Justice and the U.S. Attorney's Office for the District of Massachusetts), risks associated with intellectual property of other parties and pending or future litigation relating thereto (including without limitation the patent litigation and other related proceedings relating to EYLEA® (aflibercept) Injection), the ultimate outcome of any such proceedings and investigations, and the impact any of the foregoing may have on Regeneron's business, prospects, operating results, and financial condition. A more complete description of these and other material risks can be found in Regeneron's filings with the U.S. Securities and Exchange Commission, including its Form 10-K for the year ended December 31, 2024 and its Form 10-Q for the quarterly period ended March 31, 2025. Any forward-looking statements are made based on management's current beliefs and judgment, and the reader is cautioned not to rely on any forward-looking statements made by Regeneron. Regeneron does not undertake any obligation to update (publicly or otherwise) any forward-looking statement, including without limitation any financial projection or guidance, whether as a result of new information, future events, or otherwise. Regeneron uses its media and investor relations website and social media outlets to publish important information about the Company, including information that may be deemed material to investors. Financial and other information about Regeneron is routinely posted and is accessible on Regeneron's media and investor relations website ( and its LinkedIn page ( Sanofi Disclaimers or Forward-Looking Statements This media update contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that are not historical facts. These statements include projections and estimates regarding the marketing and other potential of the product, or regarding potential future revenues from the product. Forward-looking statements are generally identified by the words 'expects', 'anticipates', 'believes', 'intends', 'estimates', 'plans', and similar expressions. Although Sanofi's management believes that the expectations reflected in such forward-looking statements are reasonable, investors are cautioned that forward-looking information and statements are subject to various risks and uncertainties, many of which are difficult to predict and generally beyond the control of Sanofi, that could cause actual results and developments to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. These risks and uncertainties include among other things, unexpected regulatory actions or delays, or government regulation generally, that could affect the availability or commercial potential of the product, the fact that product may not be commercially successful, the uncertainties inherent in research and development, including future clinical data and analysis of existing clinical data relating to the product, including post marketing, unexpected safety, quality or manufacturing issues, competition in general, risks associated with intellectual property and any related future litigation and the ultimate outcome of such litigation, and volatile economic and market conditions, and the impact that global crises may have on us, our customers, suppliers, vendors, and other business partners, and the financial condition of any one of them, as well as on our employees and on the global economy as a whole. The risks and uncertainties also include the uncertainties discussed or identified in the public filings with the SEC and the AMF made by Sanofi, including those listed under 'Risk Factors' and 'Cautionary Statement Regarding Forward-Looking Statements' in Sanofi's annual report on Form 20-F for the year ended December 31, 2024. Other than as required by applicable law, Sanofi does not undertake any obligation to update or revise any forward-looking information or statements. All trademarks mentioned in this press release are the property of the Sanofi group except for VelociSuite and Regeneron Genetics Center. Regeneron Contacts:Media Relations Ilana YellenTel: +1 Contacts:Media RelationsSandrine GuendoulTel: +33 6 25 09 14 Evan BerlandTel: +1 Le BourhisTel: + 33 6 75 06 43 Victor RouaultTel: +33 6 70 93 71 GilbertTel: +1 UbaldiTel: +33 6 30 19 66 Investor Relations Mark HudsonTel: +1 914-847-3482 Investor RelationsThomas Kudsk LarsenTel: +44 7545 513 KaisserianTel: +33 6 47 04 12 Lauscher Tel: +1 Keita BrowneTel: +1 Pham Tel: +33 7 85 93 30 17 Elgoutni Tel: +1 617-710-3587 Châtelet Tel: +33 6 80 80 89 90 Li Tel: +33 6 84 00 90 72 1 Data on FileError in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
